Report: Hospitals Add $23.6 Billion to N.J. Economy, Plus 150,000 Jobs

PRINCETON, N.J.Jan. 3, 2019 /PRNewswire/ — New Jersey’s acute care hospitals deliver a $23.6 billion boost to the state economy, along with 150,000 jobs, according to the 2018 Economic Impact Report by the New Jersey Hospital Association.

“Healthcare is a critical part of New Jersey’s economic infrastructure,” said NJHA President and CEO Cathy Bennett. “The $23.6 billion that hospitals and health systems contribute to the state economy ripples throughout all communities via jobs, income taxes paid by employees and goods and services purchased from other businesses. And most importantly, our hospitals are open to their communities 24/7/365 to provide the care we need.”

Both the total economic impact of New Jersey hospitals and the number of jobs they provide continues to grow. In last year’s report, the total economic contributions reached $23.4 billion, and the number of jobs topped out at 144,000. In fact, healthcare is the only industry that has added jobs in the state every year from 1990 through 2017, according to data from the N.J. Department of Labor.

The report is based on information from 2017 cost reports from 71 acute care hospitals filed with the N.J. Department of Health, along with other publicly available data sources.

In other key findings, New Jersey hospitals deliver:

  • $3.5 billion in services purchased from other businesses
  • More than $9 billion in total employee salaries
  • More than $500 million in state income taxes paid by hospital employees
  • More than $565 million in charity care services to New Jersey’s working poor and other uninsured residents.

NJHA’s Economic Impact Report is available online at www.njha.com/economic-impact/2018/, where users can search for data by county and by individual hospital. In addition, totals are available by teaching hospital status and state and federal legislative districts.

SOURCE New Jersey Hospital Association (NJHA)

(PRNewsfoto/New Jersey Hospital Association)

Related Links

http://www.njha.com

Sintx Announces 30-Year Spine Fusion Data With Silicon Nitride Implants

SALT LAKE CITY, Jan. 03, 2019 (GLOBE NEWSWIRE) — SINTX Technologies (NASDAQ: SINT) today reported the independent publication of 30-year clinical outcomes of lumbar fusion surgeries, performed with silicon nitride implants. The paper titled “Anterior Lumbar Interbody Fusion Using Reaction Bonded Silicon Nitride Implants” appeared in the December 2018 edition of the World Neurosurgery journal, and the findings were also featured at the 2018 Annual Scientific Meeting of the Neurosurgical Society of Australasia.

Dr. Ralph Mobbs from the University of New South Wales, Sydney, authored the study. Dr. Mobbs stated: “This work is of historical significance, being the first clinical study of silicon nitride as an implant material, the first commercial anterior lumbar interbody fusion with a synthetic material, the first design of a spinal interbody implant with endplate porosity to promote fusion, and the longest clinical follow-up of any implant material in spine surgery. This report clearly establishes the place of silicon nitride in the annals of spine surgery,” said Professor Mobbs.

“This work reflects the only known use of silicon nitride implants, outside the spine products manufactured by our company,” said Dr. Sonny Bal, Chairman of SINTX Technologies. “Despite a much earlier material composition and implant design, silicon nitride proved itself even three decades after spinal implantation. These findings are entirely consistent with the more modern data published by us, showing earlier fusion, excellent biocompatibility, ease of radiographic imaging, and other advantages of our silicon nitride spine implants. The SINTX formulation of silicon nitride is enhanced and improved even further with sintering agents that accelerate bioactivity and confer antibacterial advantages.”

“This paper is a compelling affirmation of our full confidence in silicon nitride as the ideal spine biomaterial platform, whether as an implant, surface coating, or composite formulation with other biomaterials. This report will support our sales objectives, as we prepare an official launch in the coming months in Australia – the first place to use silicon nitride in spinal fusion surgery,” said Daniel Chon, CEO of Dallas-based CTL-Amedica, the exclusive retail channel for silicon nitride spinal implants made by SINTX Technologies.

About SINTX Technologies

SINTX Technologies is an innovative biomaterials and OEM company that develops and commercializes silicon nitride for various biomedical applications including orthopedic, dental and arthroplasty.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. A discussion of those risks and uncertainties can be found in Sintx’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 29, 2018, and in Sintx’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. Sintx undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Contacts:
SINTX Technologies
801-839-3502
IR@sintx.com

NuVasive CEO J. Christopher Barry Announces New Organizational Structure And Leadership Team

SAN DIEGOJan. 3, 2019 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced a new organizational structure and associated executive team that chief executive officer (CEO) J. Christopher (Chris) Barry has selected to lead the Company’s next phase of growth and innovation. Barry joined NuVasive as CEO on November 5, 2018.

“After assessing the Company over the past two months as CEO, it is clear that NuVasive benefits from significant talent across the organization. Our new structure will enable us to better capitalize on this talent by fostering cross-functional collaboration, consolidating complementary functions and increasing accountability,” said Barry. “I am confident this leadership team and our new structure, along with disciplined execution, will better position NuVasive to fulfill our commitments to patients, surgeons, employees and shareholders, and drive NuVasive’s success and sustainable growth.”

As part of the new organizational structure, NuVasive announced the following leadership team, all of whom will report to Barry. The following changes are effective immediately:

  • Matt Link will continue to serve as president in an expanded capacity to include direct management of NuVasive Clinical Services and Global Logistics. The integration of these functions rounds out oversight of the entire product life cycle, from development to launch to service to fulfillment, which will positively impact how the sales force brings disruptive innovation to surgeons and patients.
  • Raj Asarpota will continue to serve as executive vice president and chief financial officer, and lead the Company’s Finance, Accounting, Internal Audit and Tax functions.
  • Nate Sisitsky, Esq. will continue to serve as general counsel and corporate secretary, and lead the Company’s Legal function as well as the NuVasive Spine Foundation. In addition, he will also oversee the Company’s Real Estate and Facilities function.
  • Jim Garrett, Esq., chief compliance officer and leader of the Company’s Global Risk and Integrity (GRI) function, will assume an expanded role overseeing the Business and Quality Systems functions, including GRI, Regulatory Affairs/Quality Affairs, Information Technology, and Environmental Health & Safety.
  • Lucas Vitale is named chief human resources officer, and most recently served as vice president, Human Resources and Sales Training at NuVasive. He has been with the Company for more than four years.
  • Suzanne Hatcher will continue to lead the Company’s Internal and External Affairs functions, including Investor Relations, Public Relations and Internal Communications.
  • Dale Wolf will continue to oversee the Company’s manufacturing efforts, including the facility in West Carrollton, Ohio. He will leverage his significant prior experience, with Barry’s direct oversight, to facilitate successful operational and financial execution of the Company’s self-manufacturing efforts.

NuVasive’s Global Commercial regional leaders include Paul McClintock (U.S.), Erin McEachren (Europe), Takaaki Tanaka (Japan/China) and Jim Abraham (Australia/New Zealand).

As an outcome of streamlining top layers within the Company’s new organizational structure, the positions of executive vice president, People and Culture, and executive vice president, Global Process Transformation, previously held by Pete Leddy, Ph.D. and Stephen Rozow, respectively, have been eliminated. The Company thanks Pete and Steve for their commitment and dedication to NuVasive.

To read more about NuVasive’s leadership team, please visit www.nuvasive.com and click on the About section.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400-person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit  www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

Miach Orthopaedics Appoints Martha Shadan President and CEO

WESTBOROUGH, Massachusetts – Jan. 3, 2019 – Miach Orthopaedics, Inc. a privately held company dedicated to developing bio-engineered surgical implants for connective tissue repair, today announced that medical device industry veteran Martha Shadan has been appointed president and chief executive officer. Miach’s first product under development is the Bridge-Enhanced® ACL Repair (BEAR®) technology, currently being studied in U.S. clinical trials. Shadan brings more than 30 years of medical device executive, marketing and commercialization expertise and has been executive chairwoman of the Miach board since September 2018.

During most of 2018, Shadan served as global vice president of marketing at Smith & Nephew plc, a role she assumed after the company acquired Rotation Medical, where she was president and CEO. Shadan led the company through FDA approval and commercialization of the Rotation Medical Bioinductive Implant for rotator cuff tears (now known as REGENETEN), as well as the company’s acquisition by Smith & Nephew in December 2017.

“We are very glad to have Martha Shadan joining the Miach team,” said Martha Murray, MD, founder and chief medical officer of Miach Orthopaedics. “Her experience in the medical device space with successful commercialization of medical devices brings in a very valuable skill set, and we are very much looking forward to working with her as the CEO.”

Shadan has successfully served in a number of senior leadership positions at Zimmer, Covidien, Bristol Myers Squibb Co. and Merck Millipore. She is actively involved with the Advanced Medical Technology Association (AdvaMed), serving on the Board of Directors since 2017 and Accel Board of Directors since 2015; serving as chairwoman of the Accel Board of Directors; and being a founding member of the Leadership Circle for the Women’s Executive Network (WEN). Shadan holds a master of business administration from Northeastern University, master of science in biology from Michigan State University, and bachelor of science in biology from the University of New Hampshire.

About ACL Injuries and the BEAR Implant

Every year, approximately 200,000 anterior cruciate ligament (ACL) injuries occur in the U.S. Without treatment, the ACL does not heal, resulting in ACL reconstruction surgery being one of the most common orthopaedic procedures in the U.S. Miach Orthopaedics’ new Bridge-Enhanced® ACL Repair (BEAR®) technology is a proprietary bio-engineered sponge used as a bridging scaffold to stimulate healing of the torn ACL. It is hoped this new technology will restore more normal anatomy and function of the knee, and thus enable a higher percentage of patients to get back to activities they enjoy. The BEAR implant is an investigational device and is only available in FDA-approved clinical trials.

About Miach Orthopaedics, Inc.

Miach Orthopaedics, Inc. is a privately held company located in Westborough, Massachusetts, near Boston, dedicated to developing bio-engineered surgical implants for connective tissue repair.  The company’s initial focus is on the Bridge-Enhanced® ACL Repair (BEAR®) technology as a viable alternative to conventional ACL reconstruction for patients who have sustained an ACL injury. The BEAR technology was pioneered by Martha Murray, M.D., at the Boston Children’s Hospital Department of Orthopaedic Surgery with initial research funding provided by the NFL Players Association, Boston Children’s Hospital and the National Institutes of Health. Miach closed a $22.5 million Series A round in September 2018 led by Amzak Health Investors LLC and DSM Venturing with participation from the NFL Players Association and additional investors.  For more information on Miach Orthopaedics and its products, visit www.miachortho.com and follow the company on Twitter and LinkedIn.

Miach Orthopaedics, Inc.

+1 800-590-6995
info@miachortho.com
www.miachortho.com
Twitter     LinkedIn

Media Contact

Joni Ramirez
Merryman Communications
joni@merrymancommunications.com
+1 323-532-0746

 

Oska Wellness Debuts Next-Generation Technology Clinically Proven to Relieve Chronic Pain

CARLSBAD, Calif.Jan. 3, 2019 /PRNewswire/ — Oska Wellness, a pioneer of technology-driven wellness solutions dedicated to addressing the chronic pain epidemic in the U.S., will debut its next-generation Oska Pulse device at Pepcom’s Digital Experience! from 7:00 to 10:30 pm on Monday, January 7, 2019 at the Mirage hotel in Las Vegas. Like its predecessor, the new Oska Pulse is a revolutionary drug-free pain relief device that is clinically proven to reduce inflammation, increase circulation, improve mobility and alleviate pain using Pulsed Electromagnetic Field (PEMF) technology. Key advancements of the device provide added customer convenience and include:

  • Three times longer sessions for 90-minute PEMF pain relief sessions
  • 50 percent longer battery life – 15-hour total run time

A new CDC report found that overdoses corresponding strongly with use of synthetic opioids increased nearly 10 percent year-over-year in 2017 and, as a result, the average American life expectancy has been reduced by nearly four months for the first time since WWII. Pepcom’s Digital Experience! attendees are invited to visit Oska’s table at the show to learn more and test out the innovative new Oska Pulse device. Greg Houlgate, co-founder of Oska Wellness, will be available to discuss and demonstrate Oska Pulse, PEMF technology and how his personal experience with pain led him to recognize the need for an easy to use, affordable, drug-free pain relief alternative in the U.S.

“Chronic pain disrupts the lives of over 100 million Americans daily and is the leading cause of long-term disability in the U.S., affecting more people than diabetes, heart disease and cancer combined,” said Houlgate. “It’s very clear that the United States is fighting a battle with pain. Oska Pulse addresses this issue at the source and brings affordable, drug-free pain relief to those who need it most.”

Oska Pulse provides clinically-proven pain relief in the convenience of a wearable, portable and shareable PEMF device that seamlessly fits into any lifestyle. While PEMF technology is commonly used in doctors’ offices worldwide and is demonstrated in thousands of clinical studies to work at the source of pain and provide relief, Oska Pulse is the first device to make it available at an accessible price for home use. Unlike many other pain intervention therapies, Oska Pulse has no known side effects, is non-invasive, lightweight, portable, shareable, and provides safe, effective and affordable access to pain relief – all without medication.

The new Oska Pulse device will be available for purchase in January 2019 for $399 online at www.oskawellness.comFSAstore.comHSAstore.com and Amazon. To learn more about Oska, visit www.oskawellness.com.

About Oska Wellness

Co-founded in 2015 by Greg Houlgate, Oska Wellness is a pioneer of technology-driven wellness solutions that help people live more active lives with less pain. The brand’s cornerstone product, Oska Pulse, is a revolutionary drug-free pain relief device that is clinically proven to reduce inflammation, increase circulation, improve mobility and relieve pain. Oska Pulse utilizes Pulsed Electromagnetic Field (PEMF) technology, which is commonly used in doctors’ offices and clinically proven to work at the source of pain by accelerating the body’s ability to repair injured cells and increasing blood flow. Unlike many other pain intervention therapies, Oska Pulse has no known side effects, is non-invasive, lightweight, portable, shareable, and provides safe, effective and affordable access to pain relief – all without medication. Oska Pulse can be purchased online at www.oskawellness.comFSAstore.comHSAstore.com and Amazon. To learn more about Oska, visit www.oskawellness.com.

Contact: Megan Busch 
Rachel Kay Public Relations 
858-922-5045 
207077@email4pr.com

SOURCE Oska Wellness

Related Links

https://www.oskawellness.com

NuVasive CEO J. Christopher Barry Announces New Organizational Structure And Leadership Team

SAN DIEGOJan. 3, 2019 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced a new organizational structure and associated executive team that chief executive officer (CEO) J. Christopher (Chris) Barry has selected to lead the Company’s next phase of growth and innovation. Barry joined NuVasive as CEO on November 5, 2018.

“After assessing the Company over the past two months as CEO, it is clear that NuVasive benefits from significant talent across the organization. Our new structure will enable us to better capitalize on this talent by fostering cross-functional collaboration, consolidating complementary functions and increasing accountability,” said Barry. “I am confident this leadership team and our new structure, along with disciplined execution, will better position NuVasive to fulfill our commitments to patients, surgeons, employees and shareholders, and drive NuVasive’s success and sustainable growth.”

As part of the new organizational structure, NuVasive announced the following leadership team, all of whom will report to Barry. The following changes are effective immediately:

  • Matt Link will continue to serve as president in an expanded capacity to include direct management of NuVasive Clinical Services and Global Logistics. The integration of these functions rounds out oversight of the entire product life cycle, from development to launch to service to fulfillment, which will positively impact how the sales force brings disruptive innovation to surgeons and patients.
  • Raj Asarpota will continue to serve as executive vice president and chief financial officer, and lead the Company’s Finance, Accounting, Internal Audit and Tax functions.
  • Nate Sisitsky, Esq. will continue to serve as general counsel and corporate secretary, and lead the Company’s Legal function as well as the NuVasive Spine Foundation. In addition, he will also oversee the Company’s Real Estate and Facilities function.
  • Jim Garrett, Esq., chief compliance officer and leader of the Company’s Global Risk and Integrity (GRI) function, will assume an expanded role overseeing the Business and Quality Systems functions, including GRI, Regulatory Affairs/Quality Affairs, Information Technology, and Environmental Health & Safety.
  • Lucas Vitale is named chief human resources officer, and most recently served as vice president, Human Resources and Sales Training at NuVasive. He has been with the Company for more than four years.
  • Suzanne Hatcher will continue to lead the Company’s Internal and External Affairs functions, including Investor Relations, Public Relations and Internal Communications.
  • Dale Wolf will continue to oversee the Company’s manufacturing efforts, including the facility in West Carrollton, Ohio. He will leverage his significant prior experience, with Barry’s direct oversight, to facilitate successful operational and financial execution of the Company’s self-manufacturing efforts.

NuVasive’s Global Commercial regional leaders include Paul McClintock (U.S.), Erin McEachren (Europe), Takaaki Tanaka (Japan/China) and Jim Abraham (Australia/New Zealand).

As an outcome of streamlining top layers within the Company’s new organizational structure, the positions of executive vice president, People and Culture, and executive vice president, Global Process Transformation, previously held by Pete Leddy, Ph.D. and Stephen Rozow, respectively, have been eliminated. The Company thanks Pete and Steve for their commitment and dedication to NuVasive.

To read more about NuVasive’s leadership team, please visit www.nuvasive.com and click on the About section.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400-person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit  www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

Miach Orthopaedics Appoints Martha Shadan President and CEO

WESTBOROUGH, Massachusetts – Jan. 3, 2019 – Miach Orthopaedics, Inc. a privately held company dedicated to developing bio-engineered surgical implants for connective tissue repair, today announced that medical device industry veteran Martha Shadan has been appointed president and chief executive officer. Miach’s first product under development is the Bridge-Enhanced® ACL Repair (BEAR®) technology, currently being studied in U.S. clinical trials. Shadan brings more than 30 years of medical device executive, marketing and commercialization expertise and has been executive chairwoman of the Miach board since September 2018.

During most of 2018, Shadan served as global vice president of marketing at Smith & Nephew plc, a role she assumed after the company acquired Rotation Medical, where she was president and CEO. Shadan led the company through FDA approval and commercialization of the Rotation Medical Bioinductive Implant for rotator cuff tears (now known as REGENETEN), as well as the company’s acquisition by Smith & Nephew in December 2017.

“We are very glad to have Martha Shadan joining the Miach team,” said Martha Murray, MD, founder and chief medical officer of Miach Orthopaedics. “Her experience in the medical device space with successful commercialization of medical devices brings in a very valuable skill set, and we are very much looking forward to working with her as the CEO.”

Shadan has successfully served in a number of senior leadership positions at Zimmer, Covidien, Bristol Myers Squibb Co. and Merck Millipore. She is actively involved with the Advanced Medical Technology Association (AdvaMed), serving on the Board of Directors since 2017 and Accel Board of Directors since 2015; serving as chairwoman of the Accel Board of Directors; and being a founding member of the Leadership Circle for the Women’s Executive Network (WEN). Shadan holds a master of business administration from Northeastern University, master of science in biology from Michigan State University, and bachelor of science in biology from the University of New Hampshire.

About ACL Injuries and the BEAR Implant

Every year, approximately 200,000 anterior cruciate ligament (ACL) injuries occur in the U.S. Without treatment, the ACL does not heal, resulting in ACL reconstruction surgery being one of the most common orthopaedic procedures in the U.S. Miach Orthopaedics’ new Bridge-Enhanced® ACL Repair (BEAR®) technology is a proprietary bio-engineered sponge used as a bridging scaffold to stimulate healing of the torn ACL. It is hoped this new technology will restore more normal anatomy and function of the knee, and thus enable a higher percentage of patients to get back to activities they enjoy. The BEAR implant is an investigational device and is only available in FDA-approved clinical trials.

About Miach Orthopaedics, Inc.

Miach Orthopaedics, Inc. is a privately held company located in Westborough, Massachusetts, near Boston, dedicated to developing bio-engineered surgical implants for connective tissue repair.  The company’s initial focus is on the Bridge-Enhanced® ACL Repair (BEAR®) technology as a viable alternative to conventional ACL reconstruction for patients who have sustained an ACL injury. The BEAR technology was pioneered by Martha Murray, M.D., at the Boston Children’s Hospital Department of Orthopaedic Surgery with initial research funding provided by the NFL Players Association, Boston Children’s Hospital and the National Institutes of Health. Miach closed a $22.5 million Series A round in September 2018 led by Amzak Health Investors LLC and DSM Venturing with participation from the NFL Players Association and additional investors.  For more information on Miach Orthopaedics and its products, visit www.miachortho.com and follow the company on Twitter and LinkedIn.

Miach Orthopaedics, Inc.

+1 800-590-6995
info@miachortho.com
www.miachortho.com
Twitter     LinkedIn

Media Contact

Joni Ramirez
Merryman Communications
joni@merrymancommunications.com
+1 323-532-0746

 

Oska Wellness Debuts Next-Generation Technology Clinically Proven to Relieve Chronic Pain

CARLSBAD, Calif.Jan. 3, 2019 /PRNewswire/ — Oska Wellness, a pioneer of technology-driven wellness solutions dedicated to addressing the chronic pain epidemic in the U.S., will debut its next-generation Oska Pulse device at Pepcom’s Digital Experience! from 7:00 to 10:30 pm on Monday, January 7, 2019 at the Mirage hotel in Las Vegas. Like its predecessor, the new Oska Pulse is a revolutionary drug-free pain relief device that is clinically proven to reduce inflammation, increase circulation, improve mobility and alleviate pain using Pulsed Electromagnetic Field (PEMF) technology. Key advancements of the device provide added customer convenience and include:

  • Three times longer sessions for 90-minute PEMF pain relief sessions
  • 50 percent longer battery life – 15-hour total run time

A new CDC report found that overdoses corresponding strongly with use of synthetic opioids increased nearly 10 percent year-over-year in 2017 and, as a result, the average American life expectancy has been reduced by nearly four months for the first time since WWII. Pepcom’s Digital Experience! attendees are invited to visit Oska’s table at the show to learn more and test out the innovative new Oska Pulse device. Greg Houlgate, co-founder of Oska Wellness, will be available to discuss and demonstrate Oska Pulse, PEMF technology and how his personal experience with pain led him to recognize the need for an easy to use, affordable, drug-free pain relief alternative in the U.S.

“Chronic pain disrupts the lives of over 100 million Americans daily and is the leading cause of long-term disability in the U.S., affecting more people than diabetes, heart disease and cancer combined,” said Houlgate. “It’s very clear that the United States is fighting a battle with pain. Oska Pulse addresses this issue at the source and brings affordable, drug-free pain relief to those who need it most.”

Oska Pulse provides clinically-proven pain relief in the convenience of a wearable, portable and shareable PEMF device that seamlessly fits into any lifestyle. While PEMF technology is commonly used in doctors’ offices worldwide and is demonstrated in thousands of clinical studies to work at the source of pain and provide relief, Oska Pulse is the first device to make it available at an accessible price for home use. Unlike many other pain intervention therapies, Oska Pulse has no known side effects, is non-invasive, lightweight, portable, shareable, and provides safe, effective and affordable access to pain relief – all without medication.

The new Oska Pulse device will be available for purchase in January 2019 for $399 online at www.oskawellness.comFSAstore.comHSAstore.com and Amazon. To learn more about Oska, visit www.oskawellness.com.

About Oska Wellness

Co-founded in 2015 by Greg Houlgate, Oska Wellness is a pioneer of technology-driven wellness solutions that help people live more active lives with less pain. The brand’s cornerstone product, Oska Pulse, is a revolutionary drug-free pain relief device that is clinically proven to reduce inflammation, increase circulation, improve mobility and relieve pain. Oska Pulse utilizes Pulsed Electromagnetic Field (PEMF) technology, which is commonly used in doctors’ offices and clinically proven to work at the source of pain by accelerating the body’s ability to repair injured cells and increasing blood flow. Unlike many other pain intervention therapies, Oska Pulse has no known side effects, is non-invasive, lightweight, portable, shareable, and provides safe, effective and affordable access to pain relief – all without medication. Oska Pulse can be purchased online at www.oskawellness.comFSAstore.comHSAstore.com and Amazon. To learn more about Oska, visit www.oskawellness.com.

Contact: Megan Busch 
Rachel Kay Public Relations 
858-922-5045 
207077@email4pr.com

SOURCE Oska Wellness

Related Links

https://www.oskawellness.com

OrthoPediatrics Corp. Files Sanctions Motion Against a Former Employee and WishBone Medical, Inc.

WARSAW, Indiana, Jan. 02, 2019 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, today issued a statement from Daniel Gerritzen, Vice President and General Counsel, concerning actions it filed against Robert von Seggern, a former employee, and WishBone Medical, Inc. in an Indiana state court in late December 2018 (the “Sanctions Motion”).  These actions are part of OrthoPediatrics’ existing lawsuit against von Seggern and WishBone Medical for, in part, violations of Indiana’s and federal trade secrets statutes (OrthoPediatrics Corp. v. Robert von Seggern & WishBone Medical, Inc. Whitley Superior Court, Cause No. 92D01-1705-PL-000150).

The underlying lawsuit alleges that von Seggern stole OrthoPediatrics’ trade secrets and confidential information and then turned those over to WishBone Medical for its use in developing pediatric orthopedic products.  The Sanctions Motion requests the Whitley Superior Court to sanction von Seggern and WishBone Medical for their repeated, deliberate efforts to subvert the discovery process by refusing to produce responsive documents and information, hiding or otherwise destroying evidence, and making misstatements to OrthoPediatrics and the Court concerning the existence of responsive documents and its efforts to find and produce such materials.

“OrthoPediatrics welcomes legitimate competition because that means more kids with pediatric orthopedic conditions will have greater opportunities to be helped,” stated Gerritzen.  “However, we will not tolerate individuals or entities misappropriating our property, in part, to leapfrog years of design and testing work and avoid the significant monetary expense of bringing competing products to market.  With this in mind, we will continue to aggressively pursue every legal remedy to protect and safeguard our research and product development efforts to improve the lives of children with pediatric conditions.  This includes holding those accountable who attempt to use, without authorization, OrthoPediatrics’ trade secrets and confidential information.  The trade secrets and confidential information we have become aware von Seggern and WishBone Medical misappropriated relates to aspects of our current Trauma and Deformity Correction medical devices.  While very serious, the misappropriation does not significantly jeopardize our overall research and development pipeline.”

Gerritzen continued, “OrthoPediatrics takes active measures to protect its trade secrets and confidential information.  These safeguards continue to be refined and adapted in light of ever-changing threats. Due to its ongoing lawsuit, OrthoPediatrics will not provide any additional comments or details regarding this matter other than what is reflected in court filings and Court orders.”

Artificial Intelligence in Healthcare Spending to Hit $36B

By Jennifer Bresnick

 – The global market for artificial intelligence in healthcare is set for incredible growth over the next few years, according to new research from ReportLinker.

The AI in healthcare market is slated to expand from its current $2.1 billion to $36.1 billion in 2025, representing a staggering compound annual growth rate (CAGR) of 50.2 percent.

This rapid increase in value for a relatively new but highly impactful market will be driven largely by North American investment, with the United States at the forefront of innovation and spending.

Hospitals and physician providers will be the major investors in machine learning and artificial intelligence solutions and services, the report predicts.

“A few major factors responsible for the high share of the hospitals and providers segment include a large number of applications of AI solutions across provider settings; ability of AI systems to improve care delivery, patient experience, and bring down costs; and growing adoption of electronic health records by healthcare organizations,” said the report.

“Moreover, AI-based tools, such as voice recognition software and clinical decision support systems, help streamline workflow processes in hospitals, lower cost, improve care delivery, and enhance patient experience.”

Natural language processing (NLP) tools will play an important role in bringing these improvements to providers, continued the brief.

NLP can translate speech into text, extract concrete data elements from unstructured input, and power chatbots that offer customer service or even basic triage for low-level complaints.

These services will be valuable to consumers seeking more convenient, on-demand access to care as well as among providers looking to reduce their keyboard time and simplify interactions with their electronic health records (EHRs).

Using artificial intelligence to create more intuitive, user-friendly workflows is a top goal for EHR developers moving into 2019, especially as provider burnout continues to rise and dissatisfaction with existing products hits a fever pitch.

Traditionally consumer-focused companies, such as Google and Amazon, are also rising to the challenge of creating AI-driven tools that can leverage NLP to capture key medical interactions and improve home monitoring for individuals with chronic disease.

Combining machine learning with medical-grade or consumer-facing devices may exponentially increase the impact of both technologies, notes a separate report from Frost & Sullivan published in September of 2018.

Developing Internet of Medical Things (IoMT) strategies that match sophisticated sensors with AI-backed analytics will be key for developing the smart hospitals – and smart homes – of the future.

“Sensors, artificial intelligence, big data analytics, and blockchain are vital technologies for IoMT as they provide multiple benefits to patients and facilities alike,” said Varun Babu, Senior Research Analyst, TechVision.

“For instance, they help with the delivery of targeted and personalized medicine while simultaneously ensuring seamless communication and high productivity within smart hospitals.”

These strategies are likely to contribute significantly to the predicted growth of the general artificial intelligence market as devices become smaller, cheaper, and more accepted by consumers and providers alike.

 

READ THE REST HERE